STAT stories you may have missed
Trump’s new trade deal is bad news for the pharmaceutical industry, and they’re not mincing words.
Presidential hopeful Elizabeth Warren has some harsh words for Eli Lilly and its half-priced insulin product.
STAT’s newest health tech wizard, Erin Brodwin, unpacks the startups at the heart of Apple’s digital health strategy.
There’s some serious drama unfolding surrounding a Gilead HIV drug, and the dispute centers around an unlikely character: an otherwise unknown patent attorney working for the U.S. patent office.
PhRMA is again attempting to block a state’s efforts to curb drug prices, this time in Oregon.
Presidential hopeful Elizabeth Warren has some harsh words for Eli Lilly and its half-priced insulin product.
STAT’s newest health tech wizard, Erin Brodwin, unpacks the startups at the heart of Apple’s digital health strategy.
There’s some serious drama unfolding surrounding a Gilead HIV drug, and the dispute centers around an unlikely character: an otherwise unknown patent attorney working for the U.S. patent office.
PhRMA is again attempting to block a state’s efforts to curb drug prices, this time in Oregon.
.png)
No hay comentarios:
Publicar un comentario